Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $4.3 million.

  • Celldex Therapeutics' Accounts Payables rose 28303.41% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 28303.41%. This contributed to the annual value of $3.3 million for FY2024, which is 655.41% down from last year.
  • Celldex Therapeutics' Accounts Payables amounted to $4.3 million in Q3 2025, which was up 28303.41% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Accounts Payables registered a high of $4.3 million during Q3 2025, and its lowest value of $685000.0 during Q2 2021.
  • For the 5-year period, Celldex Therapeutics' Accounts Payables averaged around $2.3 million, with its median value being $2.3 million (2022).
  • Within the past 5 years, the most significant YoY rise in Celldex Therapeutics' Accounts Payables was 33155.51% (2024), while the steepest drop was 6893.47% (2024).
  • Quarter analysis of 5 years shows Celldex Therapeutics' Accounts Payables stood at $1.2 million in 2021, then surged by 171.99% to $3.3 million in 2022, then rose by 4.61% to $3.5 million in 2023, then dropped by 6.55% to $3.3 million in 2024, then surged by 30.69% to $4.3 million in 2025.
  • Its Accounts Payables stands at $4.3 million for Q3 2025, versus $2.1 million for Q2 2025 and $3.4 million for Q1 2025.